Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation

Fig. 6

Naringenin (Nar) reduces the release of TGF-β1. a, b Changes of cellular and secreted TGF-β1 in 4T1 cells after treatment with Nar in the absence of CHX (a Nar to untreated Control) or the presence of CHX (b Nar to CHX treatment) over time. c Flow cytometry analysis of the cellular TGF-β1 level in 4T1 cells after treatment with Nar, CHX, or the combination of Nar and CHX for 24 hours. d Western blot analysis of the cellular TGF-β1 level in 4T1 cells after treatment with Nar, Bafilomycin A (Baf), or the combination of Nar and Baf for 24 hours. e Intracellular and secreted TGF-β1 concentrations of 4T1 cells treated with Nar, Baf, or the combination of Nar with Baf for 24 hours were measured by ELISA. *P <0.05, **P <0.01, ***P <0.001. Error bars indicate SE. CHX cycloheximide, GAPDH glyceraldehyde 3-phosphate dehydrogenase, TGF transforming growth factor

Back to article page